Update on Private Placement and Placing
No summary for this filing – the full text is below.
Select text to share a quote on X · sign in to keep highlights & notes in your OBI notes
Ondine Biomedical Inc. (LON: OBI), a Canadian life sciences company, announces an update to its Private Placement announced on 24 September 2024 and the Fundraising announced on 1 November 2024.
The settlement of the Private Placement with a Canadian private investor has been delayed due to their unavoidable personal circumstances and will require additional time to complete. In light of this, settlement of the Fundraising scheduled for Nov 11 will also be delayed coinciding with the Private Placement settlement. Further updates will be provided in due course.
Ondine Biomedical Inc.
| Angelika Vance, Vice President of Corporate Communications | +001 604 838 2702 |
| Singer Capital Markets (Nominated Adviser, Joint Broker) | |
| Phil Davies, Sam Butcher | +44 (0)20 7496 3000 |
| RBC Capital Markets (Joint Broker) | |
| Rupert Walford, Kathryn Deegan | +44 (0)20 7653 4000 |
| Vane Percy & Roberts (Media Contact for Ondine Biomedial) | +44 (0)77 1000 5910 |
Simon Vane Percy, Amanda Bernard
About Ondine Biomedical Inc.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.